Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Biogen Idec
in the ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark Biogen Idec' s performance against key rivals in the ethical
pharmaceutical sector
- Assess the robust forecast sales contribution sourced from the relaunched
Tysabri franchise in the multiple sclerosis market
- Evaluate the importance of royalty revenues delivered via rituximab, which
will continue to support Biogen Idec' s strong sales growth rate out to 2012
View Cart
